Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


11 Hyperkalzämie, Osteolysen, Bisphosphonate: Literatur

Autor/en: P. Schmid, K. Possinger
Letzte Änderung: 25.01.2006
  • Berenson JR, Hillner E, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann C.
    American Society of Clinical Oncology Clinical Practice Guidelines: The role of bisphosphonates in multiple myeloma.
    J Clin Oncol 2002;20:3719-3736. PM:12202673
    [Medline]


  • Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma D, Heffernan M, Seaman J, Knight JD.
    Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.
    N Engl J Med 1996;334:488-493. PM:8559201
    [Medline]


  • Berenson JR, Rosen LS, Howell A.
    Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200. PM:11283917
    [Medline]


  • Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G.
    Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
    N Engl J Med 1998;339:357-363. PM:9691101
    [Medline]


  • Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Riechman SP, Tauer K, Neidhart J, Mallette LE, Siegel R, Van de Pol CJ.
    Comparative study of pamidronate and etidronate disodium in the treatment of cancer-related hypercalcemia.
    J Clin Oncol 1992;10:134-142. PM:1727915
    [Medline]


  • Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee C, Janjan NA, Cauley, Blumenstein BA, Albain KS, Lipton A, Brown S.
    American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer.
    J Clin Oncol 2003;21:4042-4057. PM:12963702
    [Medline]


  • Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C.
    Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate.
    J Clin Oncol 1998;16:2038-2044. PM:9626201
    [Medline]


  • Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ.
    Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
    Cancer 2000;88:1082-1090. PM:10699899
    [Medline]


  • Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J.
    Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
    J Clin Oncol 2001;19:558-567. PM:11208851
    [Medline]


  • Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf JM.
    Metastatic and histologic presentations in unknown primary cancer.
    Semin Oncol 1977;4:53-58. PM:841350
    [Medline]


  • Pavlakis N, Stockler M.
    Bisphosphonates for breast cancer.
    Cochrane Database of Systematic Reviews 2002; CD003474. PM:11869664
    http://www.cochrane.org.
    [Medline]


  • Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thurlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiebaud D.
    Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
    J Clin Oncol 1996;14:268-276. PM:8558208
    [Medline]


  • Powles T, Paterson S, Kanis JA.
    Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
    J Clin Oncol 2002;20:3219-3224. PM:12149294
    [Medline]


  • Ralston SH, Gallacher SSSJ, Patel U, Dryburgh FJ, Fraser WD, Boyle IT.
    Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989;2:1180-1182. PM:2572902
    [Medline]


  • Ralston SH, Thiebaud D, Herrmann Z, Steinhauer EU, Thürlimann B, Walls J, Lichinitser MR, Rizzoll R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ.
    Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia.
    r J Cancer 1997;75:295-300. PM:9010041
    [Medline]


  • Rosen LS, Gordon D, Kaminski M.
    Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Cancer J 2001;7:377-387. PM:11693896
    [Medline]


  • Saad F, Gleason DM, Murray R.
    A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    J Natl Cancer Inst 2002;94:1458-1468. PM:12359855
    [Medline]


  • Saarto T, Blomqvist C, Virkkunen P, Elomaa II.
    adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
    J Clin Oncol 2001;19:10-17. PM:11134190
    [Medline]


  • Theriault RL, Lipton A, Hortobagyi GN.
    Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
    J Clin Oncol 1999;17:846-854. PM:10071275
    [Medline]


  • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen B, Seaman JJ.
    Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma.
    Cancer 2003;98:1735-1744. PM:14534891
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
[Mehr]